Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Apr;49(4):1323-5.
doi: 10.1128/AAC.49.4.1323-1325.2005.

Is in vitro antibiotic combination more effective than single-drug therapy against anthrax?

Abed Athamna  1 , Muhammad Athamna, Aburashed Nura, Eli Shlyakov, Darrin J Bast, David Farrell, Ethan Rubinstein
Affiliations

Is in vitro antibiotic combination more effective than single-drug therapy against anthrax?

Abed Athamna et al. Antimicrob Agents Chemother. 2005 Apr.

Abstract

Antibiotic combinations are used to enhance antibacterial efficacy and to prevent the development of resistance. We have tested a possible synergistic effect of several antibacterial combinations on Bacillus anthracis. The in vitro activities of antibiotic combinations against two strains of B. anthracis, strain Sterne and the Russian anthrax vaccine strain STi, were tested by the fractional inhibitory concentration (FIC) method, derived from the MICs of the agents in combination, and by measuring the rate of bacterial killing over time by several antibiotic combinations. The FIC results showed that synergism against both B. anthracis strains was observed only with the combination of rifampin and clindamycin. The telithromycin-amoxicillin combination showed synergism against strain Sterne only. All other combinations were either indifferent or antagonistic. The results of the bacterial time-kill study demonstrated indifferent effects for all combinations. These in vitro results demonstrate the difficulties in obtaining synergistic combinations of antibiotics against B. anthracis.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Athamna, A., M. Athamna, N. Abu-Rashed, B. Medlej, D. J. Bast, and E. Rubinstein. 2004. Selection of Bacillus anthracis isolates resistant to antibiotics. J. Antimicrob. Chemother. 54:424-428. - PubMed
    1. Athamna, A., M. Massalha, M. Athamna, A. Nura, B. Medlej, I. Ofek, D. J. Bast., and E. Rubinstein. 2004. In vitro susceptibility of Bacillus anthracis to various antibacterial agents and their time-kill activity. J. Antimicrob. Chemother. 53:247-251. - PubMed
    1. Centers for Disease Control and Prevention. 2001. CDC update: investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax. Morb. Mortal. Wkly. Rep. 50:941-948. - PubMed
    1. Eliopoulos, G. M., and R. C. Moellering. 1991. Antimicrobial combinations, p. 432-492. In V. Lorian (ed.), Antibiotics in laboratory medicine. The Williams & Wilkins Co., Baltimore, Md.
    1. Inglesby, T. V., T. O'Toole, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. M. Friedlander, J. Gerberding, J. Hauer, J. Hughes, J. McDade, M. T. Osterholm, G. Parker, T. M. Perl, P. K. Russell, K. Tonat, et al. 2002. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287:2236-2252. - PubMed

MeSH terms